21468126
2011 May
Most children with chronic hepatitis C have minimal liver disease before adulthood, but could be at risk of progression to cirrhosis and hepatocellular carcinoma because of persistent virus replication. The results of the first controlled trial with PEG-IFN-Î±2a plus ribavirin are a step towards an appropriate treatment for these children.

